title: [Evaluation of the safety and efficacy of cefditoren pivoxil fine granules for pediatric use in pediatric patients with laryngopharyngitis and tonsillitis caused by Streptococcus pyogenes].
abstract: Rheumatic fever and acute glomerulonephritis are known to occur secondary to infection with Streptococcus pyogenes, and early elimination of the Streptococcus pyogenes by treatment with an appropriate antibiotic is required. Treatment with penicillins for 10 days has been recommended for Streptococcus pyogenes infections, but cephems are also now being used, and cefditoren pivoxil (CDTR-PI) is listed as one of the recommended drugs in the Guidelines for the Management of Respiratory Infectious Disease in Children in Japan 2007. We therefore conducted this study in order to collect appropriate use information in the clinical setting of CDTR-PI to treat Streptococcus pyogenes infections. In this study, 790 patients were enrolled in 147 institutions. Of them, 734 and 718 patients were chosen for safety and efficacy analysis, respectively. There were 11 adverse drug reactions in 11 patients, and the incidence of adverse drug reactions was 1.50% (11/734 patients). The most common adverse drug reactions were diarrhea and hematuria, and there were 3 events of each, but a positive urinalysis after administration were only obserbed without the clinical symptoms. With the exception of the 3 patients in which the patient did not return to the hospital and the outcome is unknown, the patients either recovered from all of the adverse drug reactions or they were relieved. No serious adverse drug reactions were reported in this study. The response rate was 98.5% for laryngopharyngitis (457/464 patients) and 98.4% (250/254 patients) for tonsillitis. Examination of the response rates according to patient background showed that they were high, 95% or more, in every group. The Streptococcus pyogenes eradication rate was 94.6% for laryngopharyngitis (194/205 patients) and 92.4% (110/119 patients) for tonsillitis. In summary, CDTR-PI exhibited excellent safety and efficacy in laryngopharyngitis and tonsillitis caused by Streptococcus pyogenes, and CDTR-PI was reconfirmed as a useful drug.
authors.affiliation: Pharmacovigilance Dept. Reliability & Quality Assurance Center, Meiji Seika Kaisha, Ltd.
authors.forename: Saori
authors.initials: S
authors.lastname: Kawamata
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yamada
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Sato
authors.forename: Yuji
authors.initials: Y
authors.lastname: Sasagawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Iwama
authors.forename: Masato
authors.initials: M
authors.lastname: Matumoto
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004304:Dosage Forms; D005260:Female; D006801:Humans; D007223:Infant; D007827:Laryngitis / Q000188:drug therapy* / Q000382:microbiology*; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy* / Q000382:microbiology*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013290:Streptococcal Infections; D013297:Streptococcus pyogenes / Q000302:isolation & purification; D014069:Tonsillitis / Q000188:drug therapy* / Q000382:microbiology*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004304:Dosage Forms; C057710:cefditoren pivoxil